Core Insights - The company reported a revenue of 5.296 billion yuan for Q3 2025, with a year-on-year growth of 0.07%, and a net profit of 131 million yuan, reflecting a year-on-year increase of 2.62%, indicating a recovery in performance [1] - The company announced a mid-term dividend plan for 2025, proposing a cash dividend of 0.14 yuan per share, totaling 106 million yuan, which contributes to a cumulative cash dividend of 2.175 billion yuan since its IPO, enhancing investor returns [1] - The company is undergoing a "dual-line" transformation, shifting from "transaction-based" to "relationship-based" stores, and from "sitting merchants" to "traveling merchants" [2] Financial Performance - In the first three quarters of 2025, the company's cumulative revenue exceeded 16.07 billion yuan, with a net profit of 529 million yuan [1] - The company's online sales reached approximately 2.23 billion yuan in the first three quarters, marking a year-on-year growth of 28% [2] Strategic Initiatives - The company is focusing on enhancing its supply chain collaboration, with a centralized procurement ratio of 75.2% in the first three quarters, an increase of 3.9 percentage points year-on-year [2] - The company has implemented an AI-driven approach to improve operational efficiency, with the "Old Hundred's Little Maruko AI" 2.0 version covering key business scenarios [2] Industry Context - The industry is experiencing accelerated consolidation and differentiation due to stricter healthcare regulations and intensified competition, with a net decrease of 3,395 pharmacies in Q4 2024 and 4,002 in Q1 2025 [3] - As of September 30, the company operates 15,492 stores across 18 provincial markets, positioning itself favorably amidst industry challenges [3]

Core Viewpoint - The company reported a slight increase in revenue and net profit for Q3 2025, indicating stable performance despite a decline in adjusted net profit [1] Financial Performance - The company's operating revenue reached 5.296 billion yuan, representing a year-on-year increase of 0.07% [1] - The net profit attributable to shareholders was 131 million yuan, showing a year-on-year increase of 2.62% [1] - The adjusted net profit, excluding non-recurring gains and losses, was 113 million yuan, reflecting a year-on-year decrease of 9.53% [1]

Core Insights - The company reported a slight increase in performance for Q3 2025, with revenue reaching 5.296 billion yuan, a year-on-year growth of 0.07%, and a net profit attributable to shareholders of 131 million yuan, up 2.62% year-on-year, indicating a recovery in growth rate [1] - The company announced a mid-term dividend plan for 2025, proposing a cash dividend of 0.14 yuan per share, totaling 106 million yuan, bringing the cumulative cash dividends since its IPO to 2.175 billion yuan, which is 215% of the net funds raised during the IPO [1] - The chairman and president of the company stated that the pharmaceutical retail industry is still undergoing adjustment and market clearing, and the company is focusing on dual-line transformation, supply chain optimization, AI empowerment, and professional service upgrades to improve operational performance [1] Financial Performance - In the first three quarters, the company achieved a cumulative revenue of 16.07 billion yuan and a net profit of 529 million yuan [1] - The total number of stores reached 15,492, including 9,741 direct-operated stores and 5,751 franchised stores, covering 18 provincial markets [1] Strategic Initiatives - The company has fully launched a "dual-line" transformation strategy in Q3 2025, shifting store operations from a "transactional" to a "relationship-based" model, enhancing customer service experience through cultural promotion and optimized assessment mechanisms [2] - The company has improved its centralized procurement ratio to 75.2%, an increase of 3.9 percentage points year-on-year, and has implemented projects to optimize product structure and enhance customer loyalty [2] - The self-developed AI platform "Old Bai's Little Maruko AI" has been upgraded to version 2.0, covering key scenarios such as medical insurance policies and chronic disease services, effectively improving internal efficiency and employee capabilities [2] - Online sales for the first three quarters reached approximately 2.23 billion yuan, reflecting a year-on-year growth of 28% [2]

Core Insights - The integration of medical insurance payment for purchasing medicine through Taobao Flash Purchase has become a new habit for many consumers, with over 40 cities supporting this service and reaching nearly 300 districts and counties [1] - The service significantly enhances consumer experience by providing quick delivery, with medicines delivered in as fast as 19 minutes, addressing urgent medication needs [3] Group 1: Service Coverage and User Experience - Taobao Flash Purchase's online medical insurance drug purchasing service has over 80% coverage in major cities like Shanghai and Shenzhen, with some areas exceeding 98% [3] - The service allows users to easily access medication through the Taobao app or Alipay, significantly reducing the need for physical trips to pharmacies, especially during late hours or adverse weather [5] - Common medications such as cold relief granules and ibuprofen are among the top ordered items through the medical insurance purchasing option [5] Group 2: Market Trends and Future Developments - The service is part of a broader initiative by the National Medical Insurance Administration to enhance convenience in the healthcare sector, promoting "Internet + Medical Services" [8] - Taobao Flash Purchase plans to continue exploring innovative solutions, including AI applications in the drug search process and partnerships with online hospitals for prescription drug purchases [8] - The service is particularly beneficial for elderly customers, as it reduces their need to go out, thus minimizing health risks [7]

Group 1 - The company reported a revenue of approximately 16.07 billion yuan for the first three quarters of 2023, representing a year-on-year decrease of 1% [1] - The net profit attributable to shareholders was approximately 529 million yuan, reflecting a year-on-year decline of 16.11% [1] - The basic earnings per share were 0.7 yuan, which is a decrease of 16.09% compared to the previous year [1] Group 2 - The company's market capitalization is currently 12.6 billion yuan [2]

证券代码：603883 证券简称：老百姓 公告编号：2025-059 老百姓大药房连锁股份有限公司 1 公司于2025年10月28日召开第五届董事会第十一次会议，审议通过了《关于 关于修订部分公司内部治理制度的的议案》。 部分上述修订的公司内部治理制度全文将于同日在上海证券交易所网站 （www.sse.com.cn）予以披露。 特此公告。 老百姓大药房连锁股份有限公司董事会 2025年10月28日 关于修订部分公司内部治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 为进一步规范公司运作，完善公司治理，根据《中华人民共和国公司法》《上 市公司信息披露管理办法》《上市公司股东会规则》《上市公司章程指引》《上 海证券交易所股票上市规则》等相关法律、法规和规范性文件的最新规定，结合 自身实际情况，公司拟不再设置监事会，监事会的职权由董事会审计委员会行使， 相关内部治理制度中涉及监事会、监事等相关条款不再适用，公司设立职工代表 董事，"股东大会"调整为"股东会"。相关内部治理制度的变更情况如下： | 序号 | 修订前的 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-057 老百姓大药房连锁股份有限公司 关于变更注册资本并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开了第五届董事会第十一次董事会，审议通过了《关于变更注册资本并修订 <公司章程>的议案》，本次议案尚需提交公司股东大会审议。 根据《中华人民共和国公司法》《上市公司信息披露管理办法》《上市公司股 东会规则》《上市公司章程指引》《上海证券交易所股票上市规则》等相关法律、 法规的规定，公司不再设置监事会，监事会的职权由董事会审计委员会行使，相 关内部治理制度中涉及监事会、监事等相关条款不再适用，公司设立职工代表董 事，"股东大会"调整为"股东会"，并对公司注册资本进行变更。 一、本次不再设置监事会情况 根据 2024 年 7 月 1 日起实施的《中华人民共和国公司法》、中国证监会《关 于新<公司法>配套制度规则实施相关过渡期安排》《上市公司章程指引》《 ...

高盛（中国）证券有限责任公司 关于老百姓大药房连锁股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上 市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引第 11 号——持续 督导》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关法律法规 和规范性文件的要求，高盛（中国）证券有限责任公司（以下简称"高盛中国"或"保荐 机构"）作为老百姓大药房连锁股份有限公司（以下简称"老百姓"或"公司"）2021 年度 非公开发行 A 股股票的保荐机构，就老百姓使用部分闲置募集资金暂时补充流动资金 的情况进行了专项核查，并发表如下核查意见： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准老百姓大药 房连锁股份有限公司非公开发行股票的批复》（证监许可[2021]2294 号）核准，公司以 非公开发行股票方式向特定投资者发行人民币普通股（A 股），募集资金总额为人民币 1,740,453,673.80 元，扣除不含税发行费用人民币 15,179,765.29 元后，募集资金净额为 人民币 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-060 老百姓大药房连锁股份有限公司关于使用 部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 一、募集资金基本情况 发行名称 | 2021 年度非公开发行股票 | | --- | --- | | 募集资金总额 | 174,045.37 万元 | | 募集资金净额 | 172,527.39 万元 | | 募集资金到账时间 | 2022 年 1 月 27 日 | | 前次用于暂时补充 | | 二、募集资金投资项目的基本情况 截至 2025 年 9 月 30 日，公司 2021 年度非公开发行股票募集资金余额为 14,561.3 万元（包含利息、手续费以及发行费用的影响），具体使用情况如下表 所示： | 发行名称 | 2021 | 年度非公开发行股票 | | --- | --- | --- | | 募集资金账户余额 | 14,561.3 | 万元 | 流动资金的募集资 金归还日期及金额 2025 年 10 月 2 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-061 老百姓大药房连锁股份有限公司 关于 2025 年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司2025年第三季度报告披露工作的重要提醒》等相关要求，现将老百姓大 药房连锁股份有限公司（以下简称"公司"）2025年第三季度主要经营数据披露 如下： 注："本报告期"指本季度初至本季度末3个月期间。 2、主营业务分行业、分产品、分地区情况（2025年1-9月） （1）主要业务分行业情况 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告 | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | | 减变动幅度 | | 同期增减变 | | | | | (%) | | 动幅度(%) | ...